Kamei Daigo, Tsuchiya Ken, Nitta Kosaku, Mineshima Michio, Akiba Takashi
Department of Blood Purification, Tokyo Women's Medical University, Tokyo, Japan.
Department of Medicine, Kidney Center, Tokyo Women's Medical University, Tokyo, Japan.
Nephrology (Carlton). 2018 Aug;23(8):737-743. doi: 10.1111/nep.13079.
Patients on dialysis are in a chronic carnitine-deficient state. This condition may be associated with abnormalities in fatty acid and organic acid metabolism; however, the details are unknown. We investigated the association between carnitine profiles before and after dialysis and the erythropoiesis-stimulating agent (ESA) resistance index (ERI), which is a significant prognostic factor in patients on maintenance haemodialysis.
This was a cross-sectional study. We measured the carnitine profile of 79 patients on maintenance haemodialysis before and after dialysis using liquid chromatography-tandem mass spectrometry (LC-MS/MS). The associations between the ERI and pre-dialysis carnitine profile, removal rate of various carnitines, and previously-reported ERI-related factors were investigated. Significant factors were determined with stepwise multiple regression analysis and validated with the bootstrap method. SPSS version 22.0 was used for analysis, and P < 0.05 was considered statistically significant.
The removal rate of long-chain acylcarnitine with dialysis was lower than that of short-chain or medium-chain acylcarnitines. Stepwise multiple regression analysis (n = 79) demonstrated that 3-hydroxy isovalerylcarnitine (C5-OH, P < 0.001, β = -0.469) and stearoylcarnitine (C18, P < 0.001, β = 0.390) were independent significant factors (R = 0.239) of ERI. The bootstrap method similarly indicated these two to be significant factors.
ERI positively correlated with long-chain C18 acylcarnitine and negatively correlated with short-chain C5-OH acylcarnitine. C5-OH and C18 acylcarnitines at baseline might be contributing factors in distinguishing responders from nonresponders after L-carnitine administration.
接受透析治疗的患者处于慢性肉碱缺乏状态。这种情况可能与脂肪酸和有机酸代谢异常有关;然而,具体细节尚不清楚。我们研究了透析前后肉碱谱与促红细胞生成素(ESA)抵抗指数(ERI)之间的关联,ERI是维持性血液透析患者的一个重要预后因素。
这是一项横断面研究。我们使用液相色谱 - 串联质谱法(LC - MS/MS)测量了79例维持性血液透析患者透析前后的肉碱谱。研究了ERI与透析前肉碱谱、各种肉碱的清除率以及先前报道的与ERI相关因素之间的关联。通过逐步多元回归分析确定显著因素,并使用自助法进行验证。使用SPSS 22.0版进行分析,P < 0.05被认为具有统计学意义。
透析时长链酰基肉碱的清除率低于短链或中链酰基肉碱。逐步多元回归分析(n = 79)表明,3 - 羟基异戊酰肉碱(C5 - OH,P < 0.001,β = - 0.469)和硬脂酰肉碱(C18,P < 0.001,β = 0.390)是ERI的独立显著因素(R = 0.239)。自助法同样表明这两个是显著因素。
ERI与长链C18酰基肉碱呈正相关,与短链C5 - OH酰基肉碱呈负相关。基线时的C5 - OH和C18酰基肉碱可能是区分左旋肉碱给药后反应者与无反应者的影响因素。